Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 123

1.

Impaired immune response to vaccinia virus inoculated at the site of cutaneous allergic inflammation.

Scott JE, ElKhal A, Freyschmidt EJ, MacArthur DH, McDonald D, Howell MD, Leung DY, Laouar A, Manjunath N, Bianchi T, Boes M, Oettgen HC, Geha RS.

J Allergy Clin Immunol. 2007 Dec;120(6):1382-8. Epub 2007 Sep 24.

PMID:
17889291
2.

Vaccinia virus inoculation in sites of allergic skin inflammation elicits a vigorous cutaneous IL-17 response.

Oyoshi MK, Elkhal A, Kumar L, Scott JE, Koduru S, He R, Leung DY, Howell MD, Oettgen HC, Murphy GF, Geha RS.

Proc Natl Acad Sci U S A. 2009 Sep 1;106(35):14954-9. doi: 10.1073/pnas.0904021106. Epub 2009 Aug 17.

3.

Skin inflammation in RelB(-/-) mice leads to defective immunity and impaired clearance of vaccinia virus.

Freyschmidt EJ, Mathias CB, MacArthur DH, Laouar A, Narasimhaswamy M, Weih F, Oettgen HC.

J Allergy Clin Immunol. 2007 Mar;119(3):671-9.

PMID:
17336617
4.

Filaggrin deficiency promotes the dissemination of cutaneously inoculated vaccinia virus.

Oyoshi MK, Beaupré J, Venturelli N, Lewis CN, Iwakura Y, Geha RS.

J Allergy Clin Immunol. 2015 Jun;135(6):1511-8.e6. doi: 10.1016/j.jaci.2014.12.1923. Epub 2015 Jan 30.

5.

IL-10 suppresses IL-17-mediated dermal inflammation and reduces the systemic burden of Vaccinia virus in a mouse model of eczema vaccinatum.

Darling AR, Freyschmidt EJ, Burton OT, Koleoglou KJ, Oyoshi MK, Oettgen HC.

Clin Immunol. 2014 Feb;150(2):153-60. doi: 10.1016/j.clim.2013.11.010. Epub 2013 Nov 27.

6.

Development of eczema vaccinatum in atopic mouse models and efficacy of MVA vaccination against lethal poxviral infection.

Knitlova J, Hajkova V, Voska L, Elsterova J, Obrova B, Melkova Z.

PLoS One. 2014 Dec 8;9(12):e114374. doi: 10.1371/journal.pone.0114374. eCollection 2014.

7.

Skin inflammation arising from cutaneous regulatory T cell deficiency leads to impaired viral immune responses.

Freyschmidt EJ, Mathias CB, Diaz N, MacArthur DH, Laouar A, Manjunath N, Hofer MD, Wurbel MA, Campbell JJ, Chatila TA, Oettgen HC.

J Immunol. 2010 Jul 15;185(2):1295-302. doi: 10.4049/jimmunol.0903144. Epub 2010 Jun 14.

8.

Inhibition of NK cell activity by IL-17 allows vaccinia virus to induce severe skin lesions in a mouse model of eczema vaccinatum.

Kawakami Y, Tomimori Y, Yumoto K, Hasegawa S, Ando T, Tagaya Y, Crotty S, Kawakami T.

J Exp Med. 2009 Jun 8;206(6):1219-25. doi: 10.1084/jem.20082835. Epub 2009 May 25.

9.

Susceptibility to vaccinia virus infection and spread in mice is determined by age at infection, allergen sensitization and mast cell status.

Domenico J, Lucas JJ, Fujita M, Gelfand EW.

Int Arch Allergy Immunol. 2012;158(2):196-205. doi: 10.1159/000330647. Epub 2012 Jan 26.

10.

Selective killing of vaccinia virus by LL-37: implications for eczema vaccinatum.

Howell MD, Jones JF, Kisich KO, Streib JE, Gallo RL, Leung DY.

J Immunol. 2004 Feb 1;172(3):1763-7.

11.

Cytokine milieu of atopic dermatitis skin subverts the innate immune response to vaccinia virus.

Howell MD, Gallo RL, Boguniewicz M, Jones JF, Wong C, Streib JE, Leung DY.

Immunity. 2006 Mar;24(3):341-8.

12.

Vaccinia virus-specific molecular signature in atopic dermatitis skin.

Grigoryev DN, Howell MD, Watkins TN, Chen YC, Cheadle C, Boguniewicz M, Barnes KC, Leung DY.

J Allergy Clin Immunol. 2010 Jan;125(1):153-159.e28. doi: 10.1016/j.jaci.2009.10.024.

13.

The signal transducer and activator of transcription 6 gene (STAT6) increases the propensity of patients with atopic dermatitis toward disseminated viral skin infections.

Howell MD, Gao P, Kim BE, Lesley LJ, Streib JE, Taylor PA, Zaccaro DJ, Boguniewicz M, Beck LA, Hanifin JM, Schneider LC, Hata TR, Gallo RL, Kaplan MH, Barnes KC, Leung DY.

J Allergy Clin Immunol. 2011 Nov;128(5):1006-14. doi: 10.1016/j.jaci.2011.06.003. Epub 2011 Jul 18.

14.

Protective murine and human monoclonal antibodies against eczema vaccinatum.

Tomimori Y, Kawakami Y, McCausland MM, Ando T, Koriazova L, Kato S, Kawakami T, Crotty S.

Antivir Ther. 2011;16(1):67-75. doi: 10.3851/IMP1717.

15.

Immunization with modified vaccinia virus Ankara prevents eczema vaccinatum in a murine model of atopic dermatitis.

Oyoshi MK, Wang JY, Geha RS.

J Allergy Clin Immunol. 2011 Oct;128(4):890-892.e3. doi: 10.1016/j.jaci.2011.06.042. Epub 2011 Aug 6. No abstract available.

16.

Macrophage inflammatory protein 3alpha deficiency in atopic dermatitis skin and role in innate immune response to vaccinia virus.

Kim BE, Leung DY, Streib JE, Kisich K, Boguniewicz M, Hamid QA, Howell MD.

J Allergy Clin Immunol. 2007 Feb;119(2):457-63. Epub 2006 Dec 4. Erratum in: J Allergy Clin Immunol. 2008 Nov;122(5):1007.. Kisich, Kevin [added].

17.

Inhibition of S100A11 gene expression impairs keratinocyte response against vaccinia virus through downregulation of the IL-10 receptor 2 chain.

Bin L, Howell MD, Kim BE, Hall CF, Streib JE, Leung DY.

J Allergy Clin Immunol. 2009 Aug;124(2):270-7, 277.e1. doi: 10.1016/j.jaci.2009.05.002. Epub 2009 Jul 3.

PMID:
19577285
18.

Vaccinia virus binds to the scavenger receptor MARCO on the surface of keratinocytes.

MacLeod DT, Nakatsuji T, Wang Z, di Nardo A, Gallo RL.

J Invest Dermatol. 2015 Jan;135(1):142-50. doi: 10.1038/jid.2014.330. Epub 2014 Aug 4.

19.

Vaccinia Ig ameliorates eczema vaccinatum in a murine model of atopic dermatitis.

Oyoshi MK, Ramesh N, Geha RS.

J Invest Dermatol. 2012 Apr;132(4):1299-301. doi: 10.1038/jid.2011.409. Epub 2011 Dec 22. No abstract available.

20.

Disruption of TNF-α/TNFR1 function in resident skin cells impairs host immune response against cutaneous vaccinia virus infection.

Tian T, Dubin K, Jin Q, Qureshi A, King SL, Liu L, Jiang X, Murphy GF, Kupper TS, Fuhlbrigge RC.

J Invest Dermatol. 2012 May;132(5):1425-34. doi: 10.1038/jid.2011.489. Epub 2012 Feb 9.

Supplemental Content

Support Center